This is an aggregated industry headline. Read the full story at Endpoints News →
Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
Bristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News. Krazati had received accelerated approval in 2024 in this setting. But a Phase ...
By Endpoints News
· Apr 30, 2026
· via Endpoints News
Image: Endpoints News
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
pipelineformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
PipelineFiercePharma ↗
With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain…
PipelineFiercePharma ↗
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with…
PipelineFiercePharma ↗
A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and …